Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
28 mai 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track for the second half of 2024...
Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
22 mai 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
Oral Presentation of Tonmya™ (TNX-102 SL) for Fibromyalgia; NDA preparation in progress Posters Highlighting Other TNX-102 SL Programs In Clinical Development; Long COVID and Acute Stress Disorder ...
Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia
21 mai 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials Primary...
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
15 mai 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
13 mai 2024 16h30 HE
|
Tonix Pharmaceuticals Holding Corp.
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a...
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
24 avr. 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
01 avr. 2024 16h15 HE
|
Tonix Pharmaceuticals Holding Corp.
Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya™ for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for...
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
28 mars 2024 09h32 HE
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a...
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
25 mars 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi syndrome is the most common genetic...
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
21 mars 2024 08h00 HE
|
Tonix Pharmaceuticals Holding Corp.
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder ...